Literature DB >> 17533110

RNA mutations of prox1 detected in human esophageal cancer cells by the shifted termination assay.

Takanobu Yoshimoto1, Meiko Takahashi, Satoshi Nagayama, Go Watanabe, Yutaka Shimada, Yoshiharu Sakasi, Hajime Kubo.   

Abstract

We have recently reported a novel finding that a candidate tumor suppressor gene prox1 suffered adenosine-to-inosine (A-to-I) RNA mutation without genomic mutation in a subset of human cancer cells and lost its function. Hence, screening of mutations in both cDNA and genomic DNA could be important in the analysis of causes for cancers. Here, we applied a sensitive, accurate, and simple method, called shifted termination assay (STA) for detection of an A-to-I RNA mutation (R334G) in prox1. We prepared PCR-amplified samples containing the target base of RNA mutation from cDNAs and genomic DNAs of various cell lines and clinical samples, to demonstrate that the STA method can be used to identify not only genomic mutations but also RNA mutations more effectively compared to sequencing. By means of STA, we found prox1 R334G RNA mutations but not genomic DNA mutations in 4 of 8 cases of esophageal cancers. This method can help us to detect RNA mutation effectively and progress research of a potential oncogenic principle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533110     DOI: 10.1016/j.bbrc.2007.05.071

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.

Authors:  Pramila Ramani; Aimie Norton; Michelle S Somerville; Margaret T May
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

2.  Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus.

Authors:  Jaehyuk Yoo; Jinjoo Kang; Ha Neul Lee; Berenice Aguilar; Darren Kafka; Sunju Lee; Inho Choi; Juneyong Lee; Swapnika Ramu; Juergen Haas; Chester J Koh; Young-Kwon Hong
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

3.  Altered regulation of Prox1-gene-expression in liver tumors.

Authors:  Jozsef Dudas; Tümen Mansuroglu; Federico Moriconi; Florian Haller; Joerg Wilting; Thomas Lorf; Laszlo Füzesi; Giuliano Ramadori
Journal:  BMC Cancer       Date:  2008-04-09       Impact factor: 4.430

4.  Clinico-pathological and prognostic implications of Srx, Nrf2, and PROX1 expression in gastric cancer and adjacent non-neoplastic mucosa - an immunohistochemical study.

Authors:  Abeer M Hafez; Ola A Harb; Ahmed Z Alattar; Nabila Hefzi; Rham Z Ahmed; Shady E Shaker; Amr Ibrahim; Ahmed K El-Taher
Journal:  Contemp Oncol (Pozn)       Date:  2021-01-04

Review 5.  Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma.

Authors:  Xing-Xing Huo; Shu-Jie Wang; Hang Song; Ming-de Li; Hua Yu; Meng Wang; Hong-Xiao Gong; Xiao-Ting Qiu; Yong-Fu Zhu; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

6.  Prox1 Facilitates Transfected CHO Cell Proliferation through Activation of the AKT Signaling Pathway.

Authors:  Shang-Zhi Xu
Journal:  Int J Biomed Sci       Date:  2010-03

7.  Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma.

Authors:  Tomonori Sasahira; Nobuhiro Ueda; Kazuhiko Yamamoto; Miyako Kurihara; Sayako Matsushima; Ujjal K Bhawal; Tadaaki Kirita; Hiroki Kuniyasu
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

8.  High PROX1 expression in gastric cancer predicts better survival.

Authors:  Alli Laitinen; Camilla Böckelman; Jaana Hagström; Arto Kokkola; Pauliina Kallio; Caj Haglund
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

Review 9.  The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy.

Authors:  Magdalena Rudzińska; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.